Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.52 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8693590 | 0.92 | CA1 (0.54) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL7722182 | 0.89 | CYP17A1 (0.53) | NPFFR1NPFFR2KMT2ARAB9APTPN11 | |
| SCHEMBL21224231 | 0.88 | HDAC1 (0.54) | KMT2AMEN1AURKBEGFRRAF1 | |
| SCHEMBL669133 | 0.87 | PTPN11 (0.49) | KMT2AMEN1MAPTRAB9AALDH1A1 | |
| SCHEMBL14679376 | 0.86 | POLB (0.54) | KMT2AMEN1MAPTALDH1A1AURKB | |
| SCHEMBL10845806 | 0.86 | POLB (0.53) | KMT2AMEN1MAPTALDH1A1LMNA | |
| SCHEMBL10850707 | 0.86 | CA1 (0.50) | KMT2AMEN1MAPTALDH1A1AURKB | |
| SCHEMBL9610754 | 0.86 | KMT2A (0.45) | NPFFR1NPFFR2KMT2AMEN1MAPT | |
| SCHEMBL22026644 | 0.85 | ALOX5 (0.50) | NPFFR1NPFFR2KMT2AMEN1RAB9A | |
| SCHEMBL400342 | 0.85 | CA1 (0.49) | KMT2AMEN1MAPTAURKBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2016-03-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759520-B2 | Compounds for treating cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| US-8674144-B2 | Catalyst for asymmetric hydrogenation and method for manufacturing optically active carbonyl compound using the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-03-18 | — | — | US | disclosed |
| EP-2373629-B1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-04-10 | — | — | EP | disclosed |
| EP-2373629-B1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INT (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010067067-A1 | COMPOUNDS FOR TREATING CANCER | EVOTEC AG (DE) | 2010-06-17 | — | — | WO | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2007-01-11 | — | — | US | disclosed |
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-6350762-B1 | SELECTIVELY INHIBIT THE ACTION OF N-TYPE CALCIUM CHANNEL; | AJINOMOTO CO., INC. (JP) | 2002-02-26 | — | — | US | disclosed |
| EP-1043314-A1 | NOVEL DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283249-A1 | Novel compounds which have a protective activity with respect to the action of toxins and of viruses with an intracellular mode of action | HAVCR2, MAVS, ANTXR2 | NPFFR1 1316/4885NPFFR2 1786/4885KMT2A 4248/4885 |
| US-20120136176-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION AND METHOD FOR MANUFACTURING OPTICALLY ACTIVE CARBONYL COMPOUND USING THE SAME | HMOX1, HIRA, HRH1 | NPFFR1 1681/4885NPFFR2 1854/4885KMT2A 3823/4885 |
| US-20160083355-A1 | COMPOUNDS WHICH HAVE A PROTECTIVE ACTIVITY WITH RESPECT TO THE ACTION OF TOXINS AND OF VIRUSES WITH AN INTRACELLULAR MODE OF ACTION | HAVCR2, MAVS, ANTXR2 | NPFFR1 1290/4885NPFFR2 1775/4885KMT2A 4212/4885 |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | NPFFR1 3141/4885NPFFR2 3648/4885KMT2A 153/4885 |
| US-20110312969-A1 | COMPOUNDS FOR TREATING CANCER | BCL2, BAX, BCL2A1 | NPFFR1 2787/4885NPFFR2 2854/4885KMT2A 2214/4885 |
| US-20070010536-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | NPFFR1 3141/4885NPFFR2 3648/4885KMT2A 153/4885 |
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | HAVCR2, MAVS, ANTXR2 | NPFFR1 1290/4885NPFFR2 1775/4885KMT2A 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.